Form 8-K - Current report:
SEC Accession No. 0001104659-21-137731
Filing Date
2021-11-12
Accepted
2021-11-12 10:32:29
Documents
17
Period of Report
2021-11-12
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2132744d1_8k.htm   iXBRL 8-K 30159
2 EXHIBIT 99.1 tm2132744d1_ex99-1.htm EX-99.1 17409
6 GRAPHIC tm2132744d1_ex99-1img004.jpg GRAPHIC 3539
7 GRAPHIC tm2132744d1_ex99-1img005.jpg GRAPHIC 28741
8 GRAPHIC tm2132744d1_ex99-1img006.jpg GRAPHIC 30315
9 GRAPHIC tm2132744d1_ex99-1img007.jpg GRAPHIC 27472
  Complete submission text file 0001104659-21-137731.txt   354324

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20211112.xsd EX-101.SCH 3195
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20211112_lab.xml EX-101.LAB 34594
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20211112_pre.xml EX-101.PRE 22717
10 EXTRACTED XBRL INSTANCE DOCUMENT tm2132744d1_8k_htm.xml XML 3715
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 211401164
SIC: 2834 Pharmaceutical Preparations